Evidence map›Paper›PMID 26471264›Full record

ArticleQuality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation2016

Mapping chronic liver disease questionnaire scores onto SF-6D utility values in patients with primary sclerosing cholangitis.

Evangelos Kalaitzakis, Maria Benito de Valle, Monira Rahman, Björn Lindkvist, Einar Björnsson, Roger Chapman, Nick Kontodimopoulos

Abstract read
PubMed Publisher
In one paragraph

Article in Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Evangelos KalaitzakisDigestive Disease Center, Copenhagen University Hospital/Bispebjerg, University of Copenhagen, 2400, Copenhagen, Denmark. kalvag@hotmail.com.ORCID http://orcid.org/0000-0002-9947-8914
Maria Benito de ValleInstitute of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Monira RahmanDepartment of Gastroenterology, John Radcliffe Hospital, Oxford, UK.
Björn LindkvistInstitute of Internal Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
Einar BjörnssonDepartment of Internal Medicine, Landspitali University Hospital, Reykjavik, Iceland.
Roger ChapmanDepartment of Gastroenterology, John Radcliffe Hospital, Oxford, UK.
Nick KontodimopoulosFaculty of Social Sciences, Hellenic Open University, Patras, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe chronic liver disease questionnaire (CLDQ) is a frequently used liver-specific quality of life instrument, but it does not provide information on preference-adjusted health status, which is essential for cost-utility analysis. We aimed to develop a mapping function deriving utilities from the CLDQ in primary sclerosing cholangitis (PSC).

methodsShort form-6D (SF-6D) utilities were calculated from SF-36 data collected in a recent prospective study in which unselected patients with PSC also completed the CLDQ. Ordinary least squares (OLS), generalized linear, median, and kernel regression analyses were employed to devise a mapping function predicting utilities. This was validated in three random subsamples of the cohort and in a separate sample of PSC patients following liver transplantation. Adjusted R (2) and root-mean-square error (RMSE) as well as Pearson's r coefficients and mean absolute errors between predicted and observed values were used to determine model performance.

resultsDecompensated liver disease and fatigue, systemic symptoms, and emotional distress, assessed with the CLDQ, were related to worse SF-6D utilities. The final OLS prediction model explained 66.3 % of the variance in the derivation sample. Predicted and observed utilities were strongly correlated (r = 0.807, p < 0.001), but the mean absolute error (0.0604) and adjusted RMSE (10.6 %) were of intermediate size. Similar model characteristics were observed after employment of generalized linear and median regression models and at validation.

conclusionsA model has been constructed, showing good validity predicting SF-6D utilities from CLDQ scores at the group level in PSC. Further testing is required to externally validate the model.

Indexed as

AlgorithmsHealth StatusSurveys and QuestionnairesCholangitis, SclerosingCost-Benefit AnalysisFemaleHumansLeast-Squares AnalysisLiver DiseasesLiver TransplantationMaleMiddle AgedModels, TheoreticalProspective StudiesQuality of LifeChronic liver disease questionnaireHealth-related quality of lifeHealth utilitiesLiver transplantationMappingPrimary sclerosing cholangitisSF-6D

Identifiers

PMID26471264

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.